Welcome to our dedicated page for Ptc Therapeutics SEC filings (Ticker: PTCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PTC Therapeutics, Inc. (PTCT) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation listed on the Nasdaq Global Select Market under the symbol PTCT, PTC uses SEC reports to communicate material events, financial results and key agreements related to its rare disease biopharmaceutical business.
Among the filings, investors can find Form 8-K current reports detailing quarterly financial results, such as revenue from Sephience (sepiapterin), the Duchenne muscular dystrophy franchise (Translarna and Emflaza), and royalty and collaboration revenue including Evrysdi (risdiplam). 8-K filings also describe significant corporate events, including FDA approvals like the U.S. approval of Sephience for phenylketonuria (PKU), regulatory correspondence such as a Complete Response Letter for vatiquinone in Friedreich’s ataxia, and material agreements like the Rights Satisfaction Agreement with former Censa securityholders related to sepiapterin net sales payments.
Through its periodic reports (such as Forms 10-K and 10-Q, when available), PTC Therapeutics provides more extensive information on its business, risk factors, R&D and SG&A expenses, cash position, royalty and collaboration structures, and the status of programs including Translarna, Emflaza, Sephience, votoplam, vatiquinone, Upstaza/Kebilidi, Tegsedi and Waylivra. These filings also confirm the company’s incorporation in Delaware and its principal executive offices in Warren, New Jersey.
Stock Titan enhances access to PTCT filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand revenue composition, major agreements, regulatory developments and forward-looking statements. Real-time updates from EDGAR mean new 8-Ks, 10-Qs, 10-Ks and other forms appear promptly, while Form 4 insider transaction reports and proxy materials, when filed, can offer additional insight into equity awards, executive compensation and ownership changes.
By using this filings page, investors and researchers can review the official record of how PTC Therapeutics describes its rare disease portfolio, collaborations, financial performance and risks in its own words to U.S. regulators.
PTC Therapeutics insider Matthew Klein has filed a Form 144 indicating an intent to sell 3,016 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ market. The shares, with an aggregate market value of $233,691.14, were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation.
Over the prior three months, Klein reported additional sales of the issuer’s common stock, including 3,428 shares on 12/02/2025 for gross proceeds of $271,062.93, 8,089 shares on 12/30/2025 for $619,921.55, and 5,149 shares on 01/06/2026 for $396,203.19. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about PTC Therapeutics.
Form 144 discloses a planned sale of 3,376 common shares of the issuer’s stock through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 01/07/2026. The shares have an indicated aggregate market value of $261,381.58, and the issuer has 80,288,305 common shares outstanding.
The shares to be sold were acquired on 01/07/2026 via an option granted on 01/07/2022, with the purchase price paid in cash. Over the prior three months, the seller, Mark Boulding, reported additional sales of common shares: 3,375 shares for $214,094.81 on 10/07/2025, 2,812 shares for $213,690.35 on 11/17/2025, 2,266 shares for $171,190.18 on 01/05/2026, and 1,739 shares for $133,811.88 on 01/06/2026.
PTCT shareholder Lee S. Golden filed a Form 144 notice to potentially sell 642 shares of common stock. The shares are to be sold through Fidelity Brokerage Services LLC on or about 01/07/2026 on the NASDAQ, with an aggregate market value of 49,744.60, and the issuer has 80,288,305 shares outstanding. These 642 shares were acquired on 01/05/2026 via restricted stock vesting from the issuer as compensation.
Over the past three months, Golden has sold 1,340 common shares on 01/06/2026 for gross proceeds of 103,109.78. By signing the notice, he represents that he does not know of any material adverse, non‑public information about the issuer’s current or prospective operations, and the form also contemplates the possibility that sales may be made under a Rule 10b5‑1 trading plan.
A Rule 144 notice has been filed for the planned sale of 1,503 shares of common stock, with an aggregate market value of
As context, the filing lists 80,288,305 shares of common stock outstanding. The person named in the notice, Mark Boulding, has also sold common shares of the same issuer during the past three months in several transactions, each with disclosed dates, share amounts, and gross proceeds.
PTCT filed a notice that a security holder plans to sell 1,235 shares of common stock through Fidelity Brokerage Services on NASDAQ, with an approximate sale date of 01/07/2026 and an aggregate market value of
The form also notes that Christine Utter sold 1,381 common shares on
This notice relates to a planned sale of 52 shares of common stock through Fidelity Brokerage Services LLC on or about 01/07/2026, to be traded on NASDAQ, with an indicated aggregate market value of $4,029.16. The 52 shares were acquired on 01/05/2026 from the issuer via restricted stock vesting as compensation.
Over the prior three months, Neil G. Almstead sold common shares in three transactions: 35,572 shares on 11/24/2025 for $2,852,153.65, 71,928 shares on 11/25/2025 for $6,001,524.59, and 1,279 shares on 01/06/2026 for $98,415.98. Zheng Y. Almstead sold 54 shares of common stock on 01/06/2026 for $4,155.17. The form includes a representation that the seller does not know of undisclosed material adverse information about the issuer.
A holder of PTCT common stock, identified as Eric Pauwels, has filed a notice of proposed sale under Rule 144. The notice covers 1,352 common shares to be sold through Fidelity Brokerage Services LLC, with an aggregate market value of $104,758.10 based on the filer’s calculation. The filing notes that 80,288,305 common shares were outstanding and lists the intended sale date as January 7, 2026 on the NASDAQ.
The 1,352 shares to be sold were acquired on January 5, 2026 through restricted stock vesting from the issuer as compensation. The notice also details prior sales of the issuer’s common stock by the same seller during the past three months, including 40,290 shares on December 17, 2025, 3,202 shares on December 18, 2025, 20,508 shares on December 19, 2025, and 1,789 shares on January 6, 2026, for gross proceeds of $3,038,755.33, $240,354.49, $1,584,387.54, and $137,659.26, respectively.
PTC Therapeutics insider Neil G. Almstead filed a Form 144 to potentially sell 1,026 shares of common stock through Fidelity Brokerage Services on NASDAQ around 01/07/2026. The filing notes that these shares were acquired on 01/05/2026 through restricted stock vesting from the issuer as compensation.
As context, the company had 80,288,305 common shares outstanding. Over the prior three months, Neil G. Almstead reported selling 35,572 shares for gross proceeds of 2,852,153.65 on 11/24/2025, 71,928 shares for 6,001,524.59 on 11/25/2025, and 1,279 shares for 98,415.98 on 01/06/2026. Zheng Y. Almstead reported selling 54 shares for 4,155.17 on 01/06/2026.
PTC Therapeutics chief technical operations officer Neil Gregory Almstead received new equity awards in the company. On January 2, 2026 he was granted 17,500 restricted stock units that vest in four equal annual installments starting January 2, 2027. He also indirectly holds 6,956 shares of common stock through his spouse, including 520 shares from this grant and 257 shares acquired under the employee stock purchase plan for the period ended December 31, 2025.
In addition, he received a stock option for 43,750 shares of common stock at an exercise price of $76.74 per share. This option was granted on January 2, 2026 and vests over four years, with 25% vesting on January 2, 2027 and a further 6.25% of the original shares vesting at the end of each successive three‑month period beginning April 2, 2027. After these transactions he beneficially owns 118,382 shares directly and the 6,956 shares indirectly.
PTC Therapeutics director Jerome B. Zeldis reported new equity awards from the company. On January 2, 2026, he received 4,000 shares of common stock in the form of restricted stock units, bringing his directly held common shares to 22,500. These RSUs vest over one year, with five-twelfths vesting on June 2, 2026 and the remaining seven-twelfths on January 2, 2027. He has elected to defer receipt of all vested shares until the earliest of four years from grant, six months after separation of service, a change in control event, or death.
On the same date, he was also granted a stock option for 3,475 shares of common stock with an exercise price of $76.74 per share. This option vests in twelve equal monthly installments over one year starting February 2, 2026 and expires on January 1, 2036.